You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|
|---|---|
| Published in |
Journal of Clinical Oncology, October 2012
|
| DOI | 10.1200/jco.2012.43.2674 |
| Pubmed ID | |
| Authors |
Gregory Cairncross, Meihua Wang, Edward Shaw, Robert Jenkins, David Brachman, Jan Buckner, Karen Fink, Luis Souhami, Normand Laperriere, Walter Curran, Minesh Mehta |
| Abstract |
Anaplastic oligodendrogliomas, pure (AO) and mixed (anaplastic oligoastrocytoma [AOA]), are chemosensitive, especially if codeleted for 1p/19q, but whether patients live longer after chemoradiotherapy is unknown. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 50% |
| United Kingdom | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 567 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | <1% |
| Japan | 3 | <1% |
| Brazil | 2 | <1% |
| Germany | 2 | <1% |
| Uruguay | 1 | <1% |
| Czechia | 1 | <1% |
| Korea, Republic of | 1 | <1% |
| France | 1 | <1% |
| United Kingdom | 1 | <1% |
| Other | 1 | <1% |
| Unknown | 550 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 94 | 17% |
| Other | 71 | 13% |
| Student > Ph. D. Student | 61 | 11% |
| Student > Postgraduate | 50 | 9% |
| Student > Doctoral Student | 46 | 8% |
| Other | 133 | 23% |
| Unknown | 112 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 296 | 52% |
| Neuroscience | 34 | 6% |
| Biochemistry, Genetics and Molecular Biology | 32 | 6% |
| Agricultural and Biological Sciences | 30 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | <1% |
| Other | 32 | 6% |
| Unknown | 138 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 September 2023.
All research outputs
#1,735,481
of 25,374,917 outputs
Outputs from Journal of Clinical Oncology
#4,228
of 22,047 outputs
Outputs of similar age
#11,430
of 192,681 outputs
Outputs of similar age from Journal of Clinical Oncology
#35
of 230 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,047 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 192,681 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 230 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.